Cargando…

Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study

Treating advanced or recurrent melanoma remains a challenge. Cancer cells can evade the immune system by blocking T‐cell activation through overexpression of the inhibitory receptor programmed death 1 (PD‐1) ligands. The PD‐1 inhibitor nivolumab blocks the inhibitory signal in T cells, thus overcomi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamazaki, Naoya, Kiyohara, Yoshio, Uhara, Hisashi, Uehara, Jiro, Fujimoto, Manabu, Takenouchi, Tatsuya, Otsuka, Masaki, Uchi, Hiroshi, Ihn, Hironobu, Minami, Hironobu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480079/ https://www.ncbi.nlm.nih.gov/pubmed/28342215 http://dx.doi.org/10.1111/cas.13241

Ejemplares similares

Long‐term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2019)

Five‐year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma
por: Uhara, Hisashi, et al.
Publicado: (2021)

Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2017)

Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy‐naive advanced melanoma
por: Namikawa, Kenjiro, et al.
Publicado: (2020)

Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)
por: Yamazaki, Naoya, et al.
Publicado: (2017)

Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study
por: Yokota, Kenji, et al.
Publicado: (2019)

Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post‐marketing surveillance
por: Uhara, Hisashi, et al.
Publicado: (2022)

Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma
por: Yamazaki, N., et al.
Publicado: (2015)

Phase I study of pegylated interferon‐alpha‐2b as an adjuvant therapy in Japanese patients with malignant melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2016)

Real‐world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance
por: Yamazaki, Naoya, et al.
Publicado: (2020)

Exposure–Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma
por: Bajaj, Gaurav, et al.
Publicado: (2017)

Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study)
por: Yamazaki, Naoya, et al.
Publicado: (2021)

Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON)
por: Namikawa, Kenjiro, et al.
Publicado: (2017)

Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
por: Yamazaki, N., et al.
Publicado: (2015)

Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma
por: Fujisawa, Yasuhiro, et al.
Publicado: (2019)

A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT‐01
por: Sahai, Vaibhav, et al.
Publicado: (2022)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2022)

Significance of 5-S-Cysteinyldopa as a Marker for Melanoma
por: Wakamatsu, Kazumasa, et al.
Publicado: (2020)

A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma
por: Kiyohara, Eiji, et al.
Publicado: (2022)

Myasthenic crisis and polymyositis induced by one dose of nivolumab
por: Kimura, Toshihiro, et al.
Publicado: (2016)

Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up
por: Tomita, Yoshihiko, et al.
Publicado: (2019)

Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open‐label phase 2 trial
por: Tamura, Kenji, et al.
Publicado: (2019)

Role of inflammation in previously untreated macular edema with branch retinal vein occlusion
por: Noma, Hidetaka, et al.
Publicado: (2014)

Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer
por: Koyama, Taiji, et al.
Publicado: (2021)

Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study
por: Aoki, Tomokazu, et al.
Publicado: (2021)

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
por: Long, Georgina V, et al.
Publicado: (2015)

Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan
por: Uhara, H., et al.
Publicado: (2017)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer
por: Ozaki, Yukinori, et al.
Publicado: (2022)

The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
por: Tanaka, Yoshinori, et al.
Publicado: (2017)

Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma
por: Geynisman, Daniel M., et al.
Publicado: (2022)

Short-term Clinical Outcome of Previously Untreated and Treated Schizophrenia and Impact of Duration of Untreated Psychosis
por: Bansal, Priyanka, et al.
Publicado: (2023)

Previously treated versus untreated scoliosis: are results different?
por: Zaina, Fabio, et al.
Publicado: (2014)

Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study)
por: Ishii, Maki, et al.
Publicado: (2020)

The Association of Aging-Related Polymorphisms with Susceptibility to Lung Cancer: A Case-Control Study in a Japanese Population
por: Furuie, Hironobu, et al.
Publicado: (2021)

Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas
por: Nemoto, Kenji, et al.
Publicado: (2002)

Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review
por: Nakamura, Hajime, et al.
Publicado: (2023)

Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patients
por: Yamazaki, Naoya, et al.
Publicado: (2015)

Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy
por: Shinohara, Nobuo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1pdhjv837s26ea20bfkj854luv